Infectious disease
Experts anticipated his nomination as Biden’s Attorney General instead.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
Swiss medtech company Abionic SA announced that they have developed the first COVID-19 severity test, the cSOFA (Covid Sequential Organ Failure Assessment) score, to help doctors quickly and accurately triage cases that come into emergency rooms.
The four promising treatments showed no effect on reducing mortality in ongoing Solidarity Trial.
Governments across the globe have flexed their financial muscles to secure promises of as many doses of COVID-19 vaccines as possible when they become available.
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
Biopharma companies who have COVID-19 vaccines in development, have astonished skeptics by the speed with which they have developed vaccines.. But now comes an even more daunting challenge—scaling up manufacturing and distribution.
Nucleic-acid-based assays are the gold standard for detecting the presence of the SARS-CoV-2 virus, but they eventually will be replaced with simpler and more advanced techniques, such as CRISPR-Cas, LAMP, and other faster and less-expensive methods.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
What do you think is how much time is required for vaccine development? In a pandemic, the timeline is less than normal. Want to know why? Read the article and find.
PRESS RELEASES